XML 15 R6.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
 9 Months Ended
Jun. 30, 2020
Jun. 30, 2019
CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)    
Net loss $ (24,707,557) $ (17,286,547)
net cash used in operating activities:    
Depreciation and amortization 1,442,255 513,028
Share-based payments for services 623,146 688,070
Equity based compensation 6,690,331 2,626,311
Common stock contributed to 401(k) plan 122,791 108,485
Shares issued for settlement of clinical research costs 1,769,500 1,290,000
Loss on derivative instruments 3,565,347 3,316,384
Warrants inducement expense 805,753 0
Warrant modification expense 5,554 0
Capitalized lease interest 0 95,742
(Increase)/decrease in assets:    
Receivables (192,242) 393
Prepaid expenses (969,219) 11,047
Supplies used for R&D and manufacturing (4,648) (109,587)
Increase/(decrease) in liabilities:    
Accounts payable (761,675) (3,567,182)
Accrued expenses 87,820 (113,280)
Due to employees (166,310) (3,914)
Other liabilities (815) (2,544)
Net cash used in operating activities (11,689,969) (12,433,594)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of property and equipment (1,530,327) (171,321)
Expenditures for patent costs (39,975) (115,476)
Net cash used in investing activities (1,570,302) (286,797)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from issuance of common stock 13,992,439 0
Payments of stock issuance costs (695,447) (90,224)
Proceeds from the purchase of stock by officers and directors 184,990 234,997
Proceeds from exercises of warrants 11,736,757 11,657,590
Proceeds from exercises of options 326,313 97,290
Payments on obligations under finance lease (592,766) (3,811)
Net cash provided by financing activities 24,952,286 11,895,842
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 11,692,015 (824,549)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 8,444,774 10,310,044
CASH AND CASH EQUIVALENTS, END OF PERIOD 20,136,789 9,485,495
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:    
Property and equipment included in current liabilities 121,441 0
Capitalizable patent costs included in current liabilities 0 30,000
Right of use asset acquired and liability incurred 399,032 0
Finance lease obligation included in accounts payable 775 434
Prepaid consulting services paid with issuance of common stock 11,706 (119,791)
Accrued consulting services to be paid with common stock 110,000 0
Fair value of warrant liabilities on date of exercise 3,035,325 1,900,618
Stock issuance costs included in current liabilities 30,152 8,010
Cash paid for interest $ 872,710 $ 1,355,676